Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Piper Jaffray  26 th Annual Healthcare Conference ... be held at The New York Palace in ... presentation, material information concerning the Company, its operations, strategies and ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... Hamdan Bin Rashid Al Maktoum Awards for Medical Sciences", ... Dubai, United Arab Emirates , on 15 ... ) , The Carter Center which won ... is actively involved in numerous programs that aim to ...
(Date:11/24/2014)... Nov. 24, 2014 VolitionRx Limited (OTCQB: ... for cancer and other conditions, today announced that data from ... Science for Business BioWin Day 2014, being held November 26, ... come from VolitionRx,s lung cancer pilot study, the samples for ... Hospitalier Universitaire (CHU) de Liege in Belgium ...
(Date:11/24/2014)... 24, 2014   Veracyte, Inc. (Nasdaq: ... president and chief executive officer, will present in a fireside ... Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ... The live audio webcast and subsequent replay may be accessed ... to the website at least 15 minutes prior to the ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
... management services for biopharmaceutical and medical device clinical trials, announced today ... how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) ... consider in trials using body composition measurements with DXA. , ... ...
... Value of Pharmaceuticals in a New U.S. Political ... the start of the first annual conference on ... Industry at the Loews Philadelphia Hotel. The ... insights needed to prepare for future changes in ...
... 9 Sagent Pharmaceuticals, Inc., a,privately-held specialty pharmaceutical ... injection, USP, an essential antibiotic used to treat,serious ... The 500mg single-dose vial expands ... single-dose vials and 10g pharmacy bulk package vials,launched ...
Cached Biology Technology:Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial 2
(Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
(Date:11/5/2014)... his career to understanding the Earth,s climate and ... As deputy director and regional climatologist for the ... Institute, Redmond has more than three decades of ... climate data to the general public. , At ... on December 15-19, 2014 the American Geophysical Union ...
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2When less is more: Death in moderation boosts population density in nature 2
... LAWRENCE, KAN. A new candidate gene for Specific ... directed by Mabel Rice at the University of Kansas, ... Center, and Javier Gayn of Neocodex, Seville, Spain. The ... Journal of Neurodevelopmental Disorders , was discovered by examining ...
... temperatures soar, scientists have been collecting data amid the ... These data, combined with measurements from aircraft and satellites, ... life in modern-day Athens easier during heat waves. ... months across southern Europe but the Greek capital of ...
... means Kansas State University ecologists will get more help ... opportunities for eight to 10 undergraduate students each summer ... Jumpponen, associate professors of biology, and Bruce Snyder, instructor ... National Science Foundation to help K-State continue to be ...
Cached Biology News:Researchers report gene associated with language, speech and reading disorders 2ESA helps make summer in the city more bearable 2ESA helps make summer in the city more bearable 3ESA helps make summer in the city more bearable 4
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... novel expression vectors, we in-troduced a new concept, ... at tran-scriptional level at the T7 phage promoter, ... amplifying the plasmid copy number, The main advantage ... retains practically all of the outstanding features of ...
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: surface area 21 cm 2 ...
Biology Products: